Biofortuna
Private Company
Funding information not available
Overview
Biofortuna is a privately held, revenue-generating CDMO focused on the diagnostics sector, founded in 2004 and headquartered in Liverpool, UK. The company offers a comprehensive suite of outsourced services designed to de-risk and accelerate the development and manufacturing of diagnostic assays, particularly molecular (PCR, LAMP) and immunoassays. With ISO 13485 and ISO 17025 accreditations and FDA registration, Biofortuna positions itself as a trusted, flexible partner for assay developers, helping them mitigate risk, manage demand, and accelerate time to market. Its business model is entirely service-based, with no proprietary therapeutic or diagnostic pipeline of its own.
Technology Platform
Integrated CDMO infrastructure for diagnostics, specializing in molecular (PCR, LAMP) and immunoassay development, lyophilization (Lyo beads), cell line quality control (STR profiling, mycoplasma detection), contract manufacturing, and controlled storage services.
Opportunities
Risk Factors
Competitive Landscape
Biofortuna competes in the diagnostics CDMO space against larger, global CDMOs offering broader services and smaller, niche specialists. Its differentiation lies in its integrated offering combining specialized assay development (especially lyophilization), cell line QC, and regulated manufacturing under one roof, targeting small-to-medium diagnostic innovators.